Discover 2,117 paid clinical trials in Toronto, Ontario. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 2,117
FeaturedActive & Responsive
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
for
Solid Tumor
Location: Toronto, Montreal, Grand Rapids MI, Philadelphia PA,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT06619587
Phase1, Recruiting
FeaturedActive & Responsive
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
for
Adenocarcinoma, Pancreatic Ductal
Location: Toronto, Detroit MI, Montreal, Basking Ridge NJ,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT05968326
Phase2, Recruiting
Featured
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
for
Moderately to Severely Active Ulcerative Colitis
Location: Toronto, New York NY, Lake Success NY, Atlanta GA,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 2 - 17
Code: NCT07158242
Phase3, Recruiting
Featured
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
for
Von Willebrand Disease, Type 3
Location: Toronto, Montreal, Richmond VA, St Louis MO,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 0+
Code: NCT06998524
Phase3, Recruiting
Featured
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease